Risperdal Lawsuit Update: Court Conference Scheduled for July 15, 2014

Audet & Partners, LLP reports that hundreds of Risperdal lawsuits now pending in Pennsylvania state courts are moving forward.  A conference is next scheduled for July 15, 2014, at which the parties will further discuss the further of the Risperdal litigation.

In the Philadelphia Court of Common Pleas (Risperdal Litigation, Case Number 100300296), more than 500 Risperdal lawsuits have been joined in multidistrict litigation (MDL) to facilitate factual discovery and other litigation procedures common to most of the pending lawsuits.

Audet & Partners, LLP currently represents many boys who have brought claims against Janssen Pharmaceutics, a division of Johnson & Johnson that manufactured and distributed the anti-psychotic drug.  It has been alleged that Janssen failed to provide adequate warnings that the administration of Risperdal could lead to production of Prolactin, a precursor of breast growth.  As a result, many boys have suffered from the abnormal growth of breast tissue, condition known as Gynecomastia, and have had to undergo costly and painful reconstructive surgery.

If you or a loved one has taken Risperdal and suffered from the abnormal growth of breast tissue, you are urged to contact a Risperdal lawyer at Audet & Partners, LLP for a free, confidential consultation.  You can contact us either by calling (800) 965-1461, or by completing and submitting our inquiry form on the right side of this page.

Join a class action. Call us: 800.965.1461